Abstract
Background: Mammography, used for breast cancer (BC) screening, has limitations such as decreased sensitivity in dense breasts. Currently used tumor markers are insufficient in diagnosing breast cancer. In this study, we aimed to investigate the relationship between serum levels of synaptophysin-like protein 1 (SYPL1) and BC, as well as compare SYPL1 with other blood tumor markers. Method: The study group consisted of 80 female patients with a histopathological diagnosis of invasive BC and didn’t receive any radiotherapy/chemotherapy. The control group 72 women with noprevious history of breast disease and evaluated as Breast Imaging Reporting and Data Systems (BI-RADS 1-2) on imaging. Serum SYPL1, cancer antigen 15-3 (CA 15-3) and carcinoembryonic antigen (CEA) were measured in both groups. Results: The diagnostic values of SYPL1, CEA and CA15-3 proteins in diagnosing BC were statistically significant. The sensitivity of SYPL1 was 48.75%, with a specificity of 80.56%. CA15-3 had a sensitivity of 80% and a specificity of 49.30%. There wasn’t statistically significant correlation between serum SYPL1 and tumor diameter, lymph node metastasis, distant organ metastasis, and stage.
Conclusion: The serum SYPL1 maintained a higher discriminatory ability for BC. The serum SYPL1 level can be used with high specificity in the diagnosis of BC. Although SYPL1 has low diagnostic value in BC by itself.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.